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and Jo´zef R. Lewandowski *a
Teixobactin is a new promising antibiotic that targets cell wall biosynthesis by binding to lipid II and has no
detectable resistance thanks to its unique but yet not fully understood mechanism of operation. To aid in
the structure-based design of teixobactin analogues with improved pharmacological properties, we
present a 3D structure of native teixobactin in membrane mimetics and characterise its binding to lipid II
through a combination of solution NMR and fast (90 kHz) magic angle spinning solid state NMR. In NMR
titrations, we observe a pattern strongly suggesting interactions between the backbone of the C-terminal
“cage” and the pyrophosphate moiety in lipid II. We ﬁnd that the N-terminal part of teixobactin does not
only act as a membrane anchor, as previously thought, but is actively involved in binding. Moreover,
teixobactin forms a well-structured and speciﬁc complex with lipid II, where the N-terminal part of
teixobactin assumes a b conformation that is highly prone to aggregation, which likely contributes to the
antibiotic's high bactericidal eﬃciency. Overall, our study provides several new clues to teixobactin's
modes of action.Introduction
The majority of antibiotics currently in clinical use have been
discovered by screening cultivable soil bacteria. However,
around 99% of microorganisms are uncultured, meaning that
they do not grow under laboratory conditions. Recently, several
methods to access potential antimicrobial compounds from
uncultured microorganisms were developed,1–4 of which the
iChip technology led to the discovery of teixobactin from a new
species of b-proteobacteria, Eleheria terrae.5 Teixobactin was
shown to have very good activity against many diﬃcult-to-treat
bacterial pathogens, including Mycobacterium tuberculosis, and
no resistant mutants were obtained in vitro with various
bacteria. Teixobactin binds to both lipid II and lipid III and thus
simultaneously inhibits the biosynthesis of peptidoglycan
and teichoic acids, triggering synergistic eﬀects leading to
increased cell wall damage and delocalization of autolysins.5,6rwick, Coventry, CV4 7AL, UK. E-mail: j.r.
ick, Coventry, CV4 7AL, UK
A 02138, USA
8000 Grenoble, France
tern University, Department of Biology,
ESI) available: Additional gures. NMR
ra. NMR relaxation data. PDB of the
See DOI: 10.1039/c8sc03655a
Chemistry 2018Additionally, teixobactin, in contrast to vancomycin, does not
bind mature peptidoglycan, which enables the eﬃcient killing
of bacteria with increased cell wall density such as vancomycin-
intermediate Staphylococcus aureus (VISA) against which van-
comycin is ineﬀective.6 The biosyntheses of both peptidoglycan
and teichoic acids rely on a common lipid carrier, bactoprenol,
C55-P, which is linked in both cases to a disaccharide unit via
a pyrophosphate bridge. In this work we focus on the peptido-
glycan precursor lipid II, which, apart from the lipid carrier and
the pyrophosphate, contains the main building blocks of
peptidoglycan; N-acetylmuramic acid, N-acetylglucosamine and
a pentapeptide (L-Ala-D-Glu-L-Lys/DAP-D-Ala-D-Ala; see Fig. 1d).
Lipid II biosynthesis varies, typically within the pentapeptide at
position three between Gram-positive bacteria possessing lysine
and Gram-negative bacteria diaminopimelic acid (DAP). Myco-
bacteria spp. possess DAP and can additionally modify N-acetyl-
to N-glycolyl-muramic acid.7 Several other modications to the
peptide stem or glycan strands have been discovered and are
discussed elsewhere.8,9 Teixobactin is expected to interact with
the pyrophosphate of lipid II and it can thus bind both Gram-
positive and Gram-negative variants of lipid II, regardless of
any modications to the sugars or peptides.5 Since the discovery
of teixobactin, its biosynthetic pathway and the identication of
lipid II as a primary target, a large number of studies have been
conducted to gainmore understanding on themode of action of
teixobactin, with the goal of developing analogues with better
pharmacological properties. Several groups have synthesizedChem. Sci.
Fig. 1 Structural details of teixobactin. (a) Solution NMR structure of teixobactin in DPC micelles presented from two diﬀerent views. The
20 lowest energy structures are shown. For clarity all of the protons except HN, Ha and hydroxyl protons were omitted from the ﬁgure (a PDB ﬁle
of the structure is provided in the ESI†). (b) Comparison of the “pyrophosphate binding cage” in the solution NMR structure of native teixobactin
with the crystal structure of the teixobactin analogue Ac-D1–5Arg10-teixobactin.14 The grey backbone represents a single conformer from the
solution NMR structure and orange represents the crystal structure. Note that the intramolecular hydrogen bond between Ser7 and Ala9 is
present only in a subset of the 20 lowest energy structures in the NMR structure. (c) A summary of the eﬀect of various substitutions on the
activity of teixobactin10,12–18 shown with the chemical structure of teixobactin as reference. The substitutions with a positive or very small eﬀect
on the antibacterial activity are indicated in green font. The substitutions that have a moderate eﬀect are indicated in orange font. The
substitutions that have a strong negative eﬀect are indicated in red font. (d) Chemical structure of lipid II with building blocks highlighted in
diﬀerent colours: GlcNAc indicatesN-acetylglucosamine (magenta), MurNAc indicatesN-acetylmuramic acid (red), pentapeptide signiﬁes L-Ala-
D-Glu-L-Lys/DAP-D-Ala-D-Ala (blue), CX represents the lipid tail with X indicating the number of carbons in the chain. There were two variants of
lipid II used in this study: Gram-positive (lysine in position 3 in the pentapeptide) and Gram-negative (diaminopimelic acid (DAP) in position 3 in
the pentapeptide), distinguished by the diﬀerent substituent R. The Gram-negative variant of lipid II used in this study had a native C55 lipid chain.
The Gram-positive lipid II variant was rendered water soluble by shortening the lipid tail to C15.
Chem. Sci. This journal is © The Royal Society of Chemistry 2018
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View Article Onlineteixobactin analogues to investigate the roles of the diﬀerent
residues in teixobactin and potentially nd active compounds
that are easier to make and better suited for clinical use (see
Fig. 1c for a summary of the eﬀect on antimicrobial activity by
substitution of amino acids). An NMR study of seven analogues
showed the importance of the D-amino acids for activity.10 The
residue in position 10, L-allo-enduracididine, is a non-
proteinogenic amino acid, which has been diﬃcult to synthe-
sise and hence replacing it with a naturally available amino acid
is an attractive approach. Arg10teixobactin11,12 and Lys10-
teixobactin12 showed good activity and recently several other
teixobactin analogues with diﬀerent alternatives in position 10
were synthesised and found to have good activity against
methicillin-resistant Staphylococcus aureus (MRSA), Staphylo-
coccus epidermidis and Bacillus subtilis.13 Structural details of
teixobactin analogues in isolation and some initial studies
involving teixobactin analogues and mimics of lipid II in
dimethyl sulfoxide (DMSO) and molecular dynamics simula-
tions exploring the binding space were reported in the litera-
ture.10,13–15,19 However, to date no structure of wild type
teixobactin and no high resolution structural information on
the interactions with actual lipid II have been reported. Here we
use a combination of solution and fast magic angle spinning
(MAS) solid-state NMR complemented by a uorescence based
assay to obtain insights on the interactions of wild type teix-
obactin with both Gram-negative and Gram-positive lipid II and
conformational changes of teixobactin induced by binding to
lipid II. We nd that the majority of the sites interacting with
lipid II are located on the backbone of teixobactin and that
teixobactin assumes an aggregation prone b-strand conforma-
tion for residues 2–6 upon binding lipid II. To mimic the
natural membrane environment of lipid II we used dodecyl-
phosphocholine (DPC) micelles but we also consider interac-
tions of teixobactin with a water soluble lipid II in aqueous
solution. Our data provide a rationale for understanding the
behaviour of numerous analogues of teixobactin and valuable
insights that should further guide eﬀorts to engineer teix-
obactin analogues.Results
Teixobactin in solution
Since teixobactin binds lipid II in the cytoplasmic membrane of
bacteria, we investigated its conformation in a simulated
membrane using DPC micelles. The 20 lowest energy structures
of teixobactin in DPC micelles in phosphate buﬀer determined
by solution NMR are shown in Fig. 1a (see ESI Table 1† for
details). The structures are overlaid with a crystal structure of
the teixobactin analogue Ac-D1–5Arg10-teixobactin as a hydro-
chloride salt14 (Fig. 1b). The proposed pyrophosphate binding
cage formed by residues 8–11 is nearly identical in the NMR and
crystal structures. The most obvious diﬀerences between the
structures are that the bond between Ser7C0 and D-Thr8N points
in diﬀerent directions and the side-chain of residue 10, where in
the analogue the allo-enduracididine has been replaced by
arginine. Additionally, the N-termini are diﬀerent in theThis journal is © The Royal Society of Chemistry 2018structures since residues 1–5 were replaced by an acetyl group in
the crystal structure construct.14
Structures of several analogues including teixobactin-Arg10
were also solved in DMSO by solution NMR.10 In the structure
of teixobactin-Arg10 and in contrast to the structure of native
teixobactin in DPC micelles, presented here, residues 1–7 are
largely unstructured. This discrepancy is likely due to DMSO
being used as a solvent for the teixobactin analogues, as
DMSO is known to destabilise the secondary structure and
promote disorder.20 Since, similar to other lipid II binding
antibiotics,21 the solvent environment appears to have
a potentially large eﬀect on the structure of teixobactin, we
have also performed solution NMR experiments on teix-
obactin in a phosphate buﬀer in the absence of micelles. A
comparison of the chemical shis in the two media (i.e.
aqueous solution in the presence and absence of DPC
micelles) suggests that no large conformation change (except
a slight change near residues 1 & 6) occurs between them with
most changes being attributable to hydrophobic interactions
between teixobactin and DPC micelles (with residues 2, 6, 7
and 11 being most likely to be involved in or inuenced by
binding to the micelle; see Fig. ESI1†).
It has been previously suggested that teixobactin in aqueous
solution binds lipid II in a 2 : 1 ratio,5 which could be poten-
tially explained if teixobactin dimerizes under these conditions.
To investigate the oligomeric state of teixobactin we measured
15N NMR relaxation in aqueous solution (see Fig. ESI3, Table
ESI2†). The correlation time (sc) for the overall tumbling and
subsequently the approximate size of the molecule were esti-
mated from 15N relaxation times. The relaxation measurements
indicate that teixobactin is not monomeric in aqueous solution.
The correlation time calculated from the relaxation times
corresponds much better to a dimer or a trimer than to
a monomer (see Fig. ESI3, Table ESI3†). The relaxation rates are
also consistent with considerable local exibility of the
N-terminal residues (order parameter, S2, of 0.4–0.6). Since the
N-terminus appears quite mobile we have also considered
whether the increased apparent hydrodynamic radius of teix-
obactin in solution could be potentially explained by a mono-
meric teixobactin where the molecule assumes a more extended
conformation as observed for some teixobactin analogues in
DMSO (though minimal changes in chemical shis between
teixobactin in DPC micelles and in aqueous solution do not
support such interpretation). However, all of the extended
monomers we generated resulted in underestimated values for
sc (see Fig. ESI3, Table ESI3†). Because DPC micelles dominate
the tumbling a similar method cannot be used to estimate the
oligomeric state of teixobactin in DPC micelles (see Fig. ESI4
and Table ESI2† for relaxation data). Due to the lack of any
plausible intermolecular NOEs, teixobactin in DPC micelles is
assumed to be monomeric for structure calculations, which is
a general assumption made for peptides in DPC micelles.Teixobactin–lipid II interactions
Whereas teixobactin did not exhibit any particular propensity
for aggregation in DPC micelles, we found that addition of lipidChem. Sci.
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View Article OnlineII resulted in rapid aggregation with peaks disappearing in the
solution NMR spectra due to the large size of the aggregates. We
observed the same behaviour when a water soluble variant of
lipid II, C15 lipid II as opposed to the native C55 lipid II, was
added to teixobactin in aqueous solution in the absence of DPC
micelles. This suggests that the aggregation is induced by
interactions between teixobactin and lipid II and does not
require a membrane environment. Previously, adding various
amounts of DMSO was demonstrated to facilitate obtaining
soluble antibiotic–lipid II complexes and to prevent their
aggregation and precipitation.22,23 However, we observe strong
aggregation in the teixobactin–lipid II complex even in solu-
tions containing 80% DMSO. Since in our case DMSO does not
alleviate the aggregation and because of its high potential for
articially introducing disorder and suppressing potentially
important interactions, we have avoided it in further
experiments.
To gain insights into the aggregation process we performed
a Fluorescence Resonance Energy Transfer (FRET) assay on
a series of lipid II binders. Among several tested antibiotics
including teixobactin, ramoplanin, deoxyactagardin B, mersa-
cidin and vancomycin, only ramoplanin and teixobactin
promoted aggregation of lipid II molecules (see Fig. ESI5†).
In order to determine whether the aggregation occurs due to
nonspecic or specic interactions we have also sedimented the
soluble aggregates formed between teixobactin and lipid II in
DPC micelles using ultracentrifugation and performed fast
magic angle spinning (MAS) solid-state NMR experiments. We
observed only one set of resonances in the solid state NMR
spectra, consistent with the presence of a single dominant
conformer in the sedimented complex (see Fig. 2e and ESI6, 7†).
The narrow, under the applied conditions, linewidths (at 90 kHz
spinning) 1H 0.2–0.4 ppm (120–240 Hz), 13C 0.4–0.6 ppm (60–90
Hz) and 15N 0.7 ppm (45 Hz) indicate unambiguously that the
aggregates are homogeneous in nature and are driven by
specic rather than nonspecic interactions.24 Note that even
moderate local disorder would be reected in substantial
broadening.
Interestingly, in a study by Parmar et al.15 no aggregation was
observed for teixobactin analogues in DMSO in the presence of
geranyl pyrophosphate, a lipid II mimic possessing a pyro-
phosphate and C10 isoprenyl chain but no sugar moieties or the
peptide stem. This result combined with our observations
suggests that the interaction with the sugar moieties of lipid II
may play a role in the aggregation process for the teix-
obactin : lipid II complex.
To obtain a site-specic view of the eﬀect of the binding of
teixobactin to lipid II we have performed NMR titrations in
solution, where changes in teixobactin spectra were followed as
a function of lipid II concentration. Upon addition of lipid II we
did not observe changes in chemical shis for any peaks but
rather a decrease in intensities of the peaks, which is behaviour
characteristic of slow exchange with dissociation constants, Kd,
in the low mM to nM range. To determine binding aﬃnities in
the presence of slow exchange, typically, one follows the build-
up of peak intensities of the bound form.25 This was not
possible in the case of lipid II titrations because the resonancesChem. Sci.for the bound form of teixobactin were broadened beyond
detection due to aggregation. Instead, we tted intensities of
the peaks from free teixobactin as a function of lipid II
concentration to extract apparent association constants26 (Ka is
the inverse of Kd; see eqn (1) in methods, see Fig. ESI8–11,
Tables ESI4, 5†). It should be noted that the Ka values obtained
by these ts may be higher than the actual Ka values due to the
eﬀect aggregation has on the NMR spectra. However, even if the
calculated Ka values may not be quantitative, they yield quali-
tative information on which sites of teixobactin are the most
aﬀected by the binding of lipid II either due to interaction or
conformational change upon interaction. We performed the
experiments using both native Gram-negative lipid II (dia-
minopimelic acid in position 3 of the peptide stem, see Fig. 1d)
with the full C55 lipid tail in DPC micelles (in the following we
refer to this sample as TXBDPC; see Fig. 2e) and a water soluble
version of Gram-positive lipid II (lysine in position 3 of the
peptide stem, see Fig. 1d) with a C15 lipid tail in aqueous
solution (in the following we refer to this sample as TXBaqueous;
see Fig. 2c). To facilitate the analysis, in Fig. 2b–e we have
highlighted in light blue all the sites for which the apparent Ka
is larger than the average apparent Ka and in dark blue all the
sites for which apparent Ka is larger than the average apparent
Ka plus one standard deviation.
The apparent Ka values for TXBaqueous are approximately one
order of magnitude larger than in TXBDPC, whichmight indicate
that the peptide stem of lipid II plays a role in the binding or
that the addition of DPC has an eﬀect on the binding strength.
However, due to the above-mentioned ambiguity of the Ka
values obtained from tting of disappearing peaks we limit
ourselves to qualitative comparisons only.
Although we see an overall diﬀerence between the binding
strength in TXBDPC and in TXBaqueous, the binding mode seems
to be very similar in both cases. The strongest eﬀect appears in
the same parts of teixobactin in both media. The majority of the
sites strongly aﬀected by the titration of lipid II are backbone
atoms. In fact, there are backbone atoms showing strong
aﬃnity in all residues except 2 and 3; for residue 2 data are
missing for N-H (TXBaqueous) and C
a-Ha (TXBaqueous and
TXBDPC), for residue 3 N-H and C
a-Ha show apparent Ka above
average (light blue in Fig. 2a–d) but not signicantly above
average (dark blue in Fig. 2b–e) for TXBDPC. For the side chains
there are no strongly aﬀected sites in residues 2–5, the most
strongly aﬀected side-chains include: N-Me-D-Phe1C
Me, N-Me-D-
Phe1C
b (TXBaqueous only), L-Ile6C
b, L-Ser7C
b (TXBDPC only, above
average Ka for TXBaqueous), D-Thr8C
b, D-Thr8C
g2, L-End10C
b,
L-End10C
d (TXBaqueous only, above average apparent Ka for
TXBDPC), L-Ile11C
g2(TXBDPC only), and L-Ile11C
d (TXBDPC only).
Most sites that show strong apparent aﬃnity (apparent Ka above
average plus standard deviation) in either TXBaqueous or TXBDPC
show at least apparent aﬃnity above average in the other. The
only exceptions are the N-Me-D-Phe1C
b (strong apparent aﬃnity
in TXBaqueous only) and the side chains of residue 11, where C
g2
and Cd show strong aﬃnity in TXBDPC but not in TXBaqueous. In
the backbone of L-Ile4 C
a shows strong aﬃnity in TXBaqueous
but not in TXBDPC and the NH shows strong aﬃnity in TXBDPC
but not in TXBaqueous. The deviations for the C
b of N-Me-D-Phe1This journal is © The Royal Society of Chemistry 2018
Fig. 2 Characterisation of the teixobactin–lipid II complex. (a–d) Results of solution NMR titrations of teixobactin with a water soluble C15 variant
of Gram-positive lipid II in aqueous solution (a, b) and with native C55 Gram-negative lipid II in DPC micelles (c, d). Panels b and d show the
measured apparent Ka values and plotted onto the chemical structure of teixobactin in a and c. Dark blue indicates sites with apparent Ka values
higher than the average plus one standard deviation and light blue indicates sites with apparent Ka values higher than the average. Dark grey
indicates sites with a below average apparent Ka (b and d). In a and c grey circles indicate sites for which data are not available. (e) 2D
1H-15N solid
state NMR correlation spectrum of sedimented [U13C-15N]teixobactin in complex with natural abundance Gram-negative lipid II in DPCmicelles
acquired at 600 MHz 1H Larmor frequency and 90 kHz magic angle spinning frequency. In panel e star indicates peaks folded in the 15N
dimension. The two resonances for residue 1 are due to the zwitterionic form of N-Me-D-Phe1 being the major form at pH 6.5. (f)
1H-15N (light
grey) and 1Ha-13Ca (dark grey) chemical shift perturbations between TXBDPC and TXBlipid II. Comparisons of secondary
13Ca (g), 1Ha (h) and 13Cb (i)
chemical shifts between TXBDPC (black squares) and TXBlipid II (red circles).
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View Article Onlineand for the side-chains of L-Ile11 can possibly be explained by
hydrophobic interactions with the DPC micelles which are
aﬀected due to conformational changes occurring in teix-
obactin when lipid II is added. The phenyl group of N-Me-D-
Phe1 has previously been suggested to interact through
hydrophobic interactions with the membrane and the lipid tail
of lipid II.27 The deviations for Ca and NH for residue 4 could
possibly indicate slightly diﬀerent backbone conformations in
the two samples: NH of residue 4 is among those peaks
showing largest chemical shi changes between TXBaqueousThis journal is © The Royal Society of Chemistry 2018and TXBDPC (see Fig. ESI1†). It is also possible that the
diﬀerent peptide stems between the Gram-negative lipid II
used in the titrations to TXBDPC and the Gram-positive lipid II
used in the titrations to TXBaqueous have some eﬀect on which
sites are mostly aﬀected but the available data are inconclusive
in this respect.
In our titrations we see a strong eﬀect on the backbone for
residues 4–6, which is not seen in the titration of the teix-
obactin-Ala10 analogue with geranyl pyrophosphate15 (lacking
the sugars and peptide chain compared to the native lipid II).Chem. Sci.
Chemical Science Edge Article
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View Article OnlineAbsence of indication of any specic interaction with geranyl
pyrophosphate for these residues suggests that they might be
involved in interactions with sugar moieties and possibly parts
of the peptide stem in native lipid II.
As mentioned previously due to aggregation we could not
detect the bound form of teixobactin by solution NMR but we
could study it by fast MAS solid state NMR, which is not limited
by the large size of the aggregates.24,28–30 Fig. 2e shows a cross-
polarization (CP) based 1H-15N correlation spectrum of
[U-13C,15N]teixobactin in a sedimented complex with unlabelled
Gram-negative lipid II in the presence of DPC (in the following
we refer to this sample as TXBlipid II). The high quality spectra
obtained by solid state NMR allowed for complete backbone
assignments of TXBlipid II and almost complete side-chain
assignments (the aromatic group of residue 1 was not
completely assigned).
To gain some insights into the intermolecular interactions
and conformation of teixobactin in the complex we calculated
chemical shi perturbations (CSPs, eqn (4) in methods)
between TXBDPC (solution) and TXBlipid II (solid; see Fig. 2f) and
secondary chemical shis (Fig. 2g–i). The 1H-15N CSPs are
sensitive to both binding and conformational changes and
1Ha-13Ca CSPs are mostly sensitive to conformational changes.
The large 1H-15N CSPs for residues 3–5 and 9–10 conrm the
view available from the titrations in solution that the binding of
teixobactin to lipid II extends beyond the pyrophosphate
binding cage formed by residues 8–11. The 1Ha-13Ca CSPs
suggest that notable conformational changes take place for
residues 2–7 with the conformation of residues 8–11 being very
similar to what we observe in solution for isolated teixobactin.
The conformational changes are more evident from the
secondary chemical shis, which report on secondary structure
deviations from random coil. Combined analysis of 13Ca, 1Ha
and 13Cb secondary chemical shis suggests that residues 2–6
rearrange from a random coil like conformation to a more
extended b-strand like conformation upon binding to lipid II.
Again, the back-bone conformation for residues 8–11 appears
largely unchanged upon complex formation.
Discussion
The charged side chain of the L-allo-enduracididine amino acid
at position 10 was initially thought to be important for the
antimicrobial activity and hence most of the initial work
focused on analogues of teixobactin with positively charged side
chains: End10Arg and End10Lys variants both displayed anti-
microbial activity but not as good as the wild type teix-
obactin.12,13 In the X-ray structure of Ac-D1–5Arg10-teixobactin
analogue the guanidinium side chain of Arg10 formed
a hydrogen bond to the chloride ion14 (mimicking the pyro-
phosphate of lipid II). Interestingly, according to our titrations
there is no strong interaction between the side chain nitrogens
of residue 10 and lipid II. However if we look at chemical shi
changes between TXBDPC and TXBlipid II the CSPs are large for
the side-chain NH groups; 0.44, 1.36 and 0.74 ppm for Ng, Nd
and Nz respectively, which, compared to the CSPs for the
backbone amides, would suggest that Nd is one of the mostChem. Sci.aﬀected nitrogen sites. The side-chains of D-Gln4 show even
larger chemical shi changes (the chemical shi in TXBDPC is
112 ppm for the N32 and 41.1 ppm in TXBlipid II and the
1H
chemical shis for H321 and H322 are 6.8 and 7.5 ppm in TXBDPC
and 8.5 and 11.4 ppm in TXBlipid II). The large chemical shi
changes for side-chain nitrogen can be explained by confor-
mational changes due to interactions with the carbon side-
chains in the case of End10. The unusual chemical shi for D-
Gln4 side-chain nitrogen suggests interactions with charged
moieties, e.g. D-Glu in the pentapeptide of lipid II: the only sites
with similar chemical shis for the systems deposited in BMRB
occur for glutamines in close contact with charged, mostly
negatively charged, side chains. The fact that a charged side
chain for residue 10 is not required was recently demonstrated
by creating teixobactin analogues where L-allo-End10 was
replaced by residues with hydrophobic side chains that
exhibited antimicrobial activity15,16 even at the level matching
the activity of wild type teixobactin.15 Interestingly, the best
performing analogues are the ones where the side chain can
assume a similar conformation to the one found for interacting
sites in our titrations, End10Ile and End10Leu,15 suggesting that
for the side chain of residue 10 the shape is more important
than the charge or hydrophobicity. The other residues of teix-
obactin whose replacement in analogues did not lead to an
overly detrimental eﬀect on the antimicrobial activity include
Ser3 and Ala9. Residue 3 did not show any signicant interaction
according to our titrations but backbone conformational
changes of residue 3 appear important for the activity. Accord-
ing to our titrations the side-chain of residue 9 is strongly
involved in the binding to lipid II, however it has been shown
that the alanine in position 9 can be exchanged to a lysine or
arginine without signicant loss of antimicrobial eﬀect14 (see
Fig. 1c). This would suggest that the backbone of residue 9 is
involved in the interactions but it is not important that the side-
chain is hydrophobic. The N-terminus of teixobactin has been
suggested to function primarily as an anchoring point to the cell
membrane, however our data suggest that it could have a more
involved role in the bactericidal mechanism of teixobactin by
promoting aggregation, which may explain the lower activity
seen in analogues where residues 1–5 were replaced by
a dodecanoyl group14 and why substitution of residues 1, 2, 5
and 6 is not well tolerated.16 Our data suggest that most of the
sites except the aromatic ring in the rst residue are involved in
the interactions with lipid II both in the presence and absence
of DPC micelles. The removal of the methyl group interacting
with lipid II leads only to amodest reduction of the antibacterial
activity17 but loss of the positive charge or replacement of the
methyl group with a bulkier hydrophobic group has much
greater negative impact.31 In the context of our study this could
suggest that bulky substituents interfere with the interaction
with lipid II. The removal of the aromatic ring, that is not
interacting with lipid II according to our data, leads to loss of
antibacterial activity altogether but substitution with larger
hydrophobic groups has a positive eﬀect.16,27 That larger
hydrophobic groups do not decrease the activity is consistent
with the side chain of residue 1 not being involved in binding to
lipid II but rather contributing to anchoring to the membrane.This journal is © The Royal Society of Chemistry 2018
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View Article OnlineOn the other hand, the aromatic ring could also aid the aggre-
gation process. The general chemical shi changes indicative of
b-strand formation for residues 2–6 and the assembly of large
soluble aggregates upon interaction of teixobactin and lipid II
suggest that these residues may aid in the aggregation process
(exposed b-strands are involved in an important mode for
protein–protein interactions linked to aggregation32), perhaps
by bril formation, as was previously reported for the ramo-
planin : lipid II complex22 or the type of aggregation observed
for the nisin : lipid II complex33,34 (though the precise nature of
this specic aggregate is unclear and requires further studies).
This highlights that exibility of the N-terminal part of teix-
obactin is important for its biological activity, as has been
suggested based on studies of several analogues of teixobactin
involving substitutions of amino acids in this part.10 However,
our data suggest that the conclusion of the mentioned study
should be slightly modied: it is not the disorder that is the key
(the N-terminus is mobile but well-ordered in our structure of
teixobactin in DPC micelles) but rather the range of accessible
conformations promoting intermolecular rather than intra-
molecular b-sheet formation.
Aggregation makes it diﬃcult to study structural aspects of
the teixobactin : lipid II complex using conventional methods
such as X-ray crystallography and solution NMR. However, we
have shown that ultra-fast MAS solid state NMR can be used to
gain valuable site-specic information in this system. More
investigations into the teixobactin : lipid II complex using
isotope labelled lipid II are required to resolve ambiguities in
intermolecular cross-peak assignments and to gain further
understanding into the structural arrangement of these large
aggregates.
Conclusions
The 3D structure of teixobactin in DPC micelles conrms the
presence of a C-terminal pyrophosphate binding cage previ-
ously suggested in truncated teixobactin analogues. The N-
terminal part of the peptide is well-structured in DPC
micelles, in contrast to structures of teixobactin analogues in
DMSO where it appears mostly disordered. A combination of
titrations in solution NMR and solid state NMR experiments
reveals that most of the teixobactin is involved in binding lipid
II, either via interactions or conformational changes upon
binding. The pattern of the strongest aﬀected residues is overall
very similar in both titrations using water soluble Gram-positive
lipid II in the absence of DPCmicelles and native Gram-negative
lipid II in the presence of DPC micelles, with mostly backbone
sites being aﬀected. Residues 2–6 undergo a change from coil to
b conformation upon binding of lipid II. We suggest that resi-
dues 2–6 are important for the activity due to their involvement
in aggregation of teixobactin–lipid II complexes, which in the
cell would lead to accumulation of lipid II and inhibition of cell
wall synthesis. Importantly, using solid state NMR we have for
the rst time been able to study the full complex formed
between native teixobactin and native lipid II, something that
would not be possible with other biophysical techniques such
as solution NMR and X-ray crystallography. This study paves theThis journal is © The Royal Society of Chemistry 2018way for more detailed structural analysis of aggregating anti-
biotics–substrate complexes.Experimental
Sample preparation
Lipid II was synthesized as described previously.34,35 The bio-
tinylated variant of lipid II used in the FRET experiments was
obtained by biotinylation of the N-acetylmuramyl-pentapeptide
precursor prior to the lipid II synthesis.
Natural abundance teixobactin and [U-13C,15N]teixobactin
were produced the same way by growing Eleheria terrae in R4
growth medium5 without (for natural abundance teixobactin)
and with (for labeled teixobactin) replacement of labeled
materials (purchased from Cambridge Isotope Laboratories,
Inc., Tewksbury, MA, USA). The labeled Modied Celtone R4
was prepared as 10 g D-glucose U-13C6, 1.1 g Celtone base U-
13C
U-15N, 0.5 g L-proline U-13C5
15N, 10 g MgCl2$6H2O, 4 g CaCl2-
$2H2O, 0.2 g K2SO4, 5.6 g N-[tris(hydroxymethyl)methyl]-2-
aminoethanesulfonic acid (TES), and deionized H2O to 1 L and
pH adjusted to 7.0 using KOH. 1 L of labelled media was inoc-
ulated with biomass from an agar plate and grown at 28 C for 7
days with shaking. The fermentation was centrifuged to separate
the cell biomass from the supernatant. The supernatant was
decanted into a new container and extracted with an equal
volume of butanol, while the cell pellet was extracted with
acetone and centrifuged. The acetone and butanol extracts were
combined and evaporated to dryness. The resulting residue was
dissolved in DMSO and separated by HPLC (water/acetonitrile/
0.1% TFA). Of the forty eight fractions generated, fraction 23
contained the majority of the target compound. This fraction was
then examined by LC-MS and the expected mass for fully 13C and
15N labelled teixobactin was the major ion peak ([M + H] ¼
1315.9). This fraction was dried down, resulting in 10 mg of the
desired product.Solution NMR
For preparation of TXBDPC [U-
13C,15N]teixobactin was dissolved
to a concentration of 2 or 3 mM in 10 mM NaP buﬀer, pH 6.5,
with 100 or 150 mM d38 DPC (Eurisotop). For preparation of
TXBaqueous [U-
13C,15N]teixobactin was dissolved to a concentra-
tion of 0.3 mM in 10 mM NaP buﬀer, pH 6.5. 2,2-Dimethyl-2-
silapentane-5-sulfonate (DSS) was used as internal reference.
Lipid II was dissolved in 10 mM NaP buﬀer, pH 6.5, with
150 mM d38 DPC. Water soluble lipid II was dissolved in 10 mM
NaP buﬀer, pH 6.5. All solution NMR experiments were per-
formed on a Bruker Avance II 700 MHz spectrometer equipped
with a cryo-probe, using 3 mm NMR tubes. Experiments were
performed at 25 C, additional 1H-15N and 1H-13C correlation
experiments were performed at 37 C so that assignments could
be compared with assignments obtained in solid state NMR
experiments. Initial assignments for TXBDPC were obtained
from a natural abundance teixobactin (prepared in the same
way as labelled teixobactin) using 2D experiments: 1H-13C
HSQC, 1H-15N SOFAST HMQC (0.3 s recycle delay), 1H-1H
TOCSY (70 ms mixing time), 1H-1H COSY. Assignments wereChem. Sci.
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View Article Onlineconrmed and completed from 3D experiments using
[U-13C,15N]teixobactin: BEST HNCACB (0.3 s recycle delay),
CCH-TOCSY (16.3 ms DIPSI-3 mixing time), CBCA(CO)NH (25%
non-uniform sampling (NUS) reconstructed in TopSpin using
the MDD algorithm36). The assignments were referenced to DSS
using an external reference. A 3D 15N HSQC-NOESY (200 ms
mixing time) and a 2D 1H-1H NOESY (200 ms mixing time) were
used for distance restraints in the structure calculations. 15N T1
and T2 relaxation times were measured using interleaved
pseudo 3D experiments. Relaxation delays for 15N T1 experi-
ments (s): 0.005, 0.075, 0.1, 0.2, 0.3, 0.4, 0.5, 0.65, 0.8, 1, 1.25,
1.5. Relaxation delays for 15N T2 experiments (s): 0.017, 0.034,
0.051, 0.068, 0.085, 0.102, 0.136, 0.170, 0.204, 0.254, 0.339.
Titrations with native lipid II to [U-13C,15N]teixobactin were
measured using 1H-15N SOFAST HMQC (0.3 s recycle delay)
and 1H-13C HSQC. Lipid II with a concentration of 15 mM was
titrated to the following concentrations (mM): 0.33, 0.79, 1.5,
2, 2.7, 3, 3.4, 3.7, 4, 4.3, 4, leading to a dilution of teixobactin to
a nal concentration of 2 mM from an initial concentration of
3 mM. Assignments for TXBaqueous were initially transferred
from TXBDPC using 2D experiments:
1H-15N SOFAST HMQC
(0.3 s recycle delay) and 1H-13C HSQC. The assignments were
completed using 3D experiments: HNCA and CCH-TOCSY
(16.3 ms DIPSI-3 mixing time). The assignments were refer-
enced internally to DSS. 15N T1 and T2 relaxation times were
measured using interleaved pseudo 3D experiments. Relaxa-
tion delays for 15N T1 experiments (s): 0.075, 0.1, 0.2, 0.3, 0.4,
0.6, 0.8, 1.1, 1.4. Relaxation delays for 15N T2 experiments (s):
0.017, 0.034, 0.068, 0.102, 0.136, 0.170, 0.237, 0.305. Titrations
of water soluble lipid II to [U-13C,15N]teixobactin were
measured using 1H-15N SOFAST HMQC and 1H-13C HSQC.
Water soluble lipid II with a concentration of 2.4 mM was
titrated to the following concentrations (mM): 0.05, 0.1, 0.14,
0.19, 0.23, leading to a dilution of teixobactin from 0.3 to
0.27 mM.Solid state NMR
Aer titrations of lipid II to [U-13C,15N]teixobactin (in DPC
micelles) the sample was transferred from the NMR tube,
10 mM NaP buﬀer pH 6.5, with 2% DSS was added up to 500 mL
leading to a nal concentration of approximately: 0.6 mM
[U-13C,15N]teixobactin, 1.4 mM lipid II, 45 mM d38 DPC. The
sample was sedimented by ultracentrifugation (Beckmann
Coulter Optima MAX-XP Ultracentrifuge) for 46 hours at
700 000  g, forming a solid paste. Most of the liquid was
removed and a small amount of 10 mM NaP buﬀer containing
2 mM gadolinium diethylenetriaminepentaacetic acid bisme-
thylamide (Gd(DTPA-BMA)) and 2% DSS was added to the
sediment. The sediment was packed into a 0.81 mm Samoson
rotor. To keep the sample hydrated during packing small
amounts of buﬀer with Gd(DTPA-BMA) and DSS were added to
the rotor. All experiments were recorded at a 600 MHz Bruker
Avance II spectrometer using a Samoson HXY 0.81 mm probe at
90 kHz magic angle spinning and a sample temperature of 39 
2 C measured from the water peak referenced to DSS. Proton
detection with 30 ms acquisition time was used for allChem. Sci.experiments. The addition of Gd(DTPA-BMA) enabled a recycle
delay of 0.5 s. Water suppression was achieved by 100–150 ms
slpTPPM37 at 22.5 kHz nutation frequency (14 of the spinning
speed). The following spectra were acquired: 2D 1H-13C inverse
CP (0.4 ms CP between 1H-13C and 13C-1H) 2D 1H-15N inverse CP
(1 ms CP between 1H-15N and 0.9 ms between 15N-1H), 3D
hCANH (0.4 ms CP between 1H-13C, 11 ms between 13C-15N,
0.9 ms between 15N-1H), 3D hCONH (2.5 ms CP between 1H-13C,
11 ms between 13C-15N, 0.9 ms between 15N-1H). 3D hCCH
TOCSY (0.4 ms CP between 1H-13C and 13C-1H, 16.3 ms DIPSI-3
mixing time at 10 kHz nutation frequency) 3D hCOCAHA
DREAM (2.5 ms CP between 1H-13CO, 0.4 ms CP between
13CA-1HA, 7 ms DREAM between 13CO-13CA at 45 kHz nutation
frequency, 12 of the spinning speed).NMR data analysis
TopSpin 3.2 was used to process all spectra. The spectra were
assigned in NMRFAM Sparky.38 Structure calculation of TXBDPC
was performed using UNIO 10 with Cyana 2.1 39 as molecular
dynamics soware using NOEs as structural restraints. Raw
spectra (1H-1H 2DNOESY and 15N 3DHSQC-NOESY) were used as
input into the structure calculation. Automatic peak picking and
NOE assignments were achieved by UNIO ATNOS-CANDID.40,41
Cyana library entries for D-amino acids were produced using
CyLib:42 D-glutamine (converted from DGN.cif), D-allo-isoleucine
(converted from 28J.cif), D-threonine (converted from DTH.cif).
A Cyana library entry for N-methylated-D-phenylalanine was
initially converted by Cylib from ZAE.cif and slightly modied by
producing a .cor le in Cyana containing the new ZAE residue as
the rst residue and a peptide bond to another amino acid. The
amide proton was added in UCSF Chimera43 and a pdb le was
exported and read in MOLMOL44 where coordinates were expor-
ted as a library le. The library le was edited manually in a text
editor to t to the Cyana library format. The .cif les were ob-
tained from http://www.bpc.uni-frankfurt.de/guentert/wiki/
index.php/Cyana_Residue_Library_Entries, except for D-allo-
isoleucine (28J.cif), which was obtained from http://
www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/
28J. A Cyana library entry for allo-enduracididine was produced
from a drawing of the chemical structure in ChemSketch
(ACDLabs Freeware 2012) including peptide bonds to residues
before and aer. The chemical structure was exported as a .mol
le and converted to PDB in UCSF Chimera.43 MOLMOL44 was
used to write coordinate les and the Cyana library entry was
nalized by manually rearranging the atoms, adding pseudo
atoms and torsion angles in a text editor (PSPAD editor).
Peak integrals from TopSpin were exported to MatLab where
a single decaying exponential function was used to t the R1 and
R2 relaxation data. Errors were calculated by aMonte Carlo error
estimation. A random number between 0 and 1 was multiplied
with the integral error, which was based on the noise level
compared to the signal for each peak, and added to the recal-
culated integrals. The tting was then repeated 2000 times with
a new random number between 0 and 1 generated each time.
Two times the standard deviations of the R1 or R2 values
received from the ts for each residue were used as errors.This journal is © The Royal Society of Chemistry 2018
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View Article OnlineThe correlation times (sc) for TXBaqueous and TXBDPC were
calculated from the 15N T1 and T2 relaxation times and the
15N
resonance frequency (nN), 71 MHz at a 16.4 T NMR magnet
(700 MHz 1H Larmor frequency) using eqn (1):
scz
1
4pnN
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
6
T1
T2
 7
r
(1)
which is generally used for rigid protein molecules in the
limit of slow molecular motion (sc [ 0.5 ns), using high
magnetic eld (1H Larmor frequency $ 500 MHz).45
To determine binding aﬃnities the peak intensities of
unbound teixobactin (TXBDPC or TXBaqueous) were measured in
the titration spectra and tted to eqn (2) (based on eqn (6) in
ref. 25):
P ¼ m
2n½Pt ð Kd  ½Lt þ n½PtÞ
þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
4Kdn½Pt þ ð Kd þ ½Lt  n½PtÞ2
q
(2)
where P is the normalized peak intensity, m ¼ 1 if the point
without an added ligand is included and m is tted if the point
without an added ligand is not included, n is the molar ratio for
binding (lipid II/teixobactin), [Lt] is ligand concentration (lipid
II), [Pt] is protein concentration (teixobactin). The data points
used for the tting were: 0.33, 0.79, 1.5, 2, 2.7, 3 (mM) lipid II for
TXBDPC and 0.05, 0.1, 0.14, 0.19, 0.23 (mM) water soluble lipid II
for TXBaqueous. The tting of the data was done by minimization
of the c2 target function (eqn (3)):
c2 ¼
XXi;calc  Xi;exp2
si;exp2
(3)
where Xi are the data sets and si the corresponding error. Errors
for the Kd ts were calculated in the same way as for the relax-
ation data using 500 steps in the Monte Carlo error
estimation.
Chemical shi perturbations were calculated as Euclidian
distances25 (eqn (4)):
CSP ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
2

dH
2 þ adX2
r
(4)
where d is the diﬀerence in chemical shi between TXBaqueous
and TXBDPC or between TXBDPC and TXBlipid II, a ¼ 0.14 if x ¼
15N and a ¼ 0.3 if x ¼ 13C.
FRET. 1 mM biotinylated lipid II was labelled with
streptavidin-conjugated FRET dyes (HTRF, CisBio) and incu-
bated with ramoplanin, teixobactin, deoxyactagardine B, mer-
sacidin and vancomycin at concentrations ranging between 0.5
and 32 mM. Samples were incubated for 30 min at ambient
temperature and FRET magnitude was measured in a time-
resolved manner, using the Clariostar plate reader (BMG Lab-
tech). The experiments were performed in triplicates. Full
reaction composition: 1 mM biotin–DAP–lipid II, 1  HTRF
labelling mixture (terbium cryptate, d2), 50 mM bis–Tris
propane pH 8.5, 10 mM MgCl2, 20 mM NaCl, 0.05% Triton X-
100, 1% glycerol.This journal is © The Royal Society of Chemistry 2018Author contributions
C. O¨. and J. R. L. designed and analysed the NMR experiments
and wrote the paper, C. O¨. performed the NMR experiments,
C. O¨. and T. H. performed the NMR structure calculation. G.
P. W. and C. G. D. designed and analysed the FRET experiments,
G. P. W. performed the FRET experiments. C. G. D. and A. J. L.
optimized lipid II synthesis and analysis, C. O¨., G. P. W., A. C. C.,
J. A. T. and A. J. L. produced and characterised lipid II. D. E. H.,
A. L. S. and A. J. P. produced and characterised the natural
abundance teixobactin and [U-13C,15N]teixobactin. The manu-
script was written through contributions from all authors.Conﬂicts of interest
The following authors, A. J. Peoples, A. L. Spoering, D. E. Hughes,
and K. Lewis declare competing nancial interests as they are
employees and consultants of NovoBiotic Pharmaceuticals.Data availability
NMR assignments were deposited in the BMRB under accession
numbers 27478 (TXBDPC), 27479 (TXBaqueous) and 27480 (TXBlipid II).
Raw NMR data are available from http://wrap.warwick.ac.uk/
108554/.Acknowledgements
The research leading to these results has received funding from
the Bill & Melinda Gates Foundation (grant OPP1160394, and
OPP1132809), European Research Council under the European
Union's Seventh Framework Programme (FP/2007–2013)/ERC
Grant Agreement 639907. J. R. L. also acknowledges funding
from EPSRC Grant EP/L025906/1, BBSRC Grant BB/L022761/1 &
BB/R010218/1. A. J. L., J. A. T., A. C. C. and C. G. D. acknowledge
funding from AMR Cross Council funding MR/N002679/1. C. O¨.
and G. P. W. acknowledge funding from the European Union
under a Marie Curie Initial Training Network FP7-PEOPLE-
2012-ITN Grant Agreement Number 316630 CAS-IDP. We
thank Peter Gu¨ntert for providing the CyLib soware and
Tobias Madl for providing Gd(DTPA-BMA). Molecular graphics
and analyses were performed with the UCSF Chimera package.
Chimera is developed by the Resource for Biocomputing,
Visualization, and Informatics at the University of California,
San Francisco (supported by NIGMS P41-GM103311).Notes and references
1 T. Kaeberlein, K. Lewis and S. S. Epstein, Science, 2002, 296,
1127–1129.
2 D. Nichols, N. Cahoon, E. M. Trakhtenberg, L. Pham,
A. Mehta, A. Belanger, T. Kanigan, K. Lewis and
S. S. Epstein, Appl. Environ. Microbiol., 2010, 76, 2445–2450.
3 A. D'Onofrio, J. M. Crawford, E. J. Stewart, K. Witt, E. Gavrish,
S. Epstein, J. Clardy and K. Lewis, Chem. Biol., 2010, 17, 254–
264.Chem. Sci.
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
0 
Se
pt
em
be
r 2
01
8.
 D
ow
nl
oa
de
d 
on
 1
0/
1/
20
18
 9
:4
6:
56
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online4 E. Gavrish, C. S. Sit, S. Cao, O. Kandror, A. Spoering,
A. Peoples, L. Ling, A. Fetterman, D. Hughes, A. Bissell,
H. Torrey, T. Akopian, A. Mueller, S. Epstein, A. Goldberg,
J. Clardy and K. Lewis, Chem. Biol., 2014, 21, 509–518.
5 L. L. Ling, T. Schneider, A. J. Peoples, A. L. Spoering,
I. Engels, B. P. Conlon, A. Mueller, T. F. Scha¨berle,
D. E. Hughes, S. Epstein, M. Jones, L. Lazarides, V. a
Steadman, D. R. Cohen, C. R. Felix, K. A. Fetterman,
W. P. Millett, A. G. Nitti, A. M. Zullo, C. Chen and K. Lewis,
Nature, 2015, 517, 455–459.
6 T. Homma, A. Nuxoll, A. B. Gandt, P. Ebner, I. Engels,
T. Schneider, F. Go¨tz, K. Lewis and B. P. Conlon,
Antimicrob. Agents Chemother., 2016, 60, 6510–6517.
7 D. Mu¨nch and H. G. Sahl, Biochim. Biophys. Acta, Biomembr.,
2015, 1848, 3062–3071.
8 W. Vollmer, D. Blanot and M. a. de Pedro, FEMS Microbiol.
Rev., 2008, 32, 149–167.
9 W. Vollmer, FEMS Microbiol. Rev., 2008, 32, 287–306.
10 A. Parmar, S. H. Prior, A. Iyer, C. S. Vincent, D. Van
Lysebetten, E. Breukink, A. Madder, E. J. Taylor and
I. Singh, Chem. Commun., 2017, 53, 2016–2019.
11 Y. E. Jad, G. A. Acosta, T. Naicker, M. Ramtahal, A. El-Faham,
T. Govender, H. G. Kruger, B. G. de la Torre and F. Albericio,
Org. Lett., 2015, 17, 6182–6185.
12 H. Yang, K. H. Chen and J. S. Nowick, ACS Chem. Biol., 2016,
11, 1823–1826.
13 A. Parmar, A. Iyer, D. G. Lloyd, C. S. Vincent, S. H. Prior,
A. Madder, E. J. Taylor and I. Singh, Chem. Commun., 2017,
53, 7788–7791.
14 H. Yang, D. R. Du Bois, J. W. Ziller and J. S. Nowick, Chem.
Commun., 2017, 53, 2772–2775.
15 A. Parmar, A. Iyer, S. H. Prior, D. G. Lloyd, E. T. Leng Goh,
C. S. Vincent, T. Palmai-Pallag, C. Z. Bachrati, E. Breukink,
A. Madder, R. Lakshminarayanan, E. J. Taylor and I. Singh,
Chem. Sci., 2017, 8, 8183–8192.
16 K. H. Chen, S. P. Le, X. Han, J. M. Frias and J. S. Nowick,
Chem. Commun., 2017, 53, 11357–11359.
17 C. Wu, Z. Pan, G. Yao, W.Wang, L. Fang andW. Su, RSC Adv.,
2017, 7, 1923–1926.
18 S. A. H. Abdel Monaim, S. Noki, E. J. Ramchuran, A. El-
Faham, F. Albericio and B. G. de la Torre, Molecules, 2017,
22, 1–9.
19 Y. Liu, Y. Liu, M. B. Chan-Park and Y. Mu, Sci. Rep., 2017, 7,
17197.
20 M. Jackson and H. H. Mantsch, Biochim. Biophys. Acta, 1991,
1078, 231–235.
21 S.-T. D. Hsu, E. Breukink, G. Bierbaum, H.-G. Sahl, B. de
Kruijﬀ, R. Kaptein, N. A. J. van Nuland and
A. M. J. J. Bonvin, J. Biol. Chem., 2003, 278, 13110–13117.
22 P. Cudic, J. K. Kranz, D. C. Behenna, R. G. Kruger,
H. Tadesse, A. J. Wand, Y. I. Veklich, J. W. Weisel and
D. G. McCaﬀerty, Proc. Natl. Acad. Sci. U. S. A., 2002, 99,
7384–7389.
23 S.-T. D. Hsu, E. Breukink, E. Tischenko, M. A. G. Lutters,
B. de Kruijﬀ, R. Kaptein, A. M. J. J. Bonvin and N. A. J. van
Nuland, Nat. Struct. Mol. Biol., 2004, 11, 963–967.Chem. Sci.24 J. M. Lamley, D. Iuga, C. O¨ster, H.-J. Sass, M. Rogowski,
A. Oss, J. Past, A. Reinhold, S. Grzesiek, A. Samoson and
J. R. Lewandowski, J. Am. Chem. Soc., 2014, 136, 16800–
16806.
25 M. P. Williamson, Prog. Nucl. Magn. Reson. Spectrosc., 2013,
73, 1–16.
26 M. Jenner, S. Kosol, D. Griﬃths, P. Prasongpholchai,
L. Manzi, A. S. Barrow, J. E. Moses, N. J. Oldham,
J. R. Lewandowski and G. L. Challis, Nat. Chem. Biol., 2018,
14, 270–275.
27 Y. Zong, X. Sun, H. Gao, K. J. Meyer, K. Lewis and Y. Rao,
J. Med. Chem., 2018, 61, 3409–3421.
28 A. Mainz, S. Jehle, B.-J. J. van Rossum, H. Oschkinat and
B. Reif, J. Am. Chem. Soc., 2009, 131, 15968–15969.
29 A. Loquet, N. G. Sgourakis, R. Gupta, K. Giller, D. Riedel,
C. Goosmann, C. Griesinger, M. Kolbe, D. Baker, S. Becker
and A. Lange, Nature, 2012, 486, 276–279.
30 C. Gardiennet, A. K. Schu¨tz, A. Hunkeler, B. Kunert,
L. Terradot, A. Bo¨ckmann and B. H. Meier, Angew. Chem.,
Int. Ed., 2012, 51, 7855–7858.
31 S. A. H. Abdel Monaim, Y. E. Jad, G. A. Acosta, T. Naicker,
E. J. Ramchuran, A. El-Faham, T. Govender, H. G. Kruger,
B. G. de la Torre and F. Albericio, RSC Adv., 2016, 6,
73827–73829.
32 J. a. Siepen, S. E. Radford and D. R. Westhead, Protein Sci.,
2003, 12, 2348–2359.
33 K. M. Scherer, J. H. Spille, H. G. Sahl, F. Grein and
U. Kubitscheck, Biophys. J., 2015, 108, 1114–1124.
34 E. Breukink, H. E. Van Heusden, P. J. Vollmerhaus,
E. Swiezewska, L. Brunner, S. Walker, A. J. R. Heck and
B. De Kruijﬀ, J. Biol. Chem., 2003, 278, 19898–19903.
35 A. J. Lloyd, A. M. Gilbey, A. M. Blewett, G. De Pascale, A. El
Zoeiby, R. C. Levesque, A. C. Catherwood, A. Tomasz,
T. D. H. Bugg, D. I. Roper and C. G. Dowson, J. Biol.
Chem., 2008, 283, 6402–6417.
36 V. Y. Orekhov and V. A. Jaravine, Prog. Nucl. Magn. Reson.
Spectrosc., 2011, 59, 271–292.
37 J. R. Lewandowski, J. Sein, H. J. Sass, S. Grzesiek,
M. Blackledge and L. Emsley, J. Am. Chem. Soc., 2010, 132,
8252–8254.
38 W. Lee, M. Tonelli and J. L. Markley, Bioinformatics, 2015, 31,
1325–1327.
39 P. Gu¨ntert, C. Mumenthaler and K. Wu¨thrich, J. Mol. Biol.,
1997, 273, 283–298.
40 T. Herrmann, P. Gu¨ntert and K. Wu¨thrich, J. Biomol. NMR,
2002, 24, 171–189.
41 T. Herrmann, P. Gu¨ntert and K. Wu¨thrich, J. Mol. Biol., 2002,
319, 209–227.
42 E. M. Yilmaz and P. Gu¨ntert, J. Biomol. NMR, 2015, 63, 21–37.
43 E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch,
D. M. Greenblatt, E. C. Meng and T. E. Ferrin, J. Comput.
Chem., 2004, 25, 1605–1612.
44 R. Koradi, M. Billeter and K. Wu¨thrich, J. Mol. Graphics,
1996, 14, 51–55.
45 J. Cavanagh, J. W. Fairbrother, A. G. Palmer, M. Rance and
N. J. Skelton, Protein NMR Spectroscopy: Principles and
Practice, Elsevier, 2nd edn, 2007.This journal is © The Royal Society of Chemistry 2018
